In the last trading session, 1.23 million shares of the NovoCure Ltd (NASDAQ:NVCR) were traded, and its beta was 0.75. Most recently the company’s share price was $27.96, and it changed around $1.36 or 5.11% from the last close, which brings the market valuation of the company to $3.18B. NVCR currently trades at a discount to its 52-week high of $32.60, offering almost -16.6% off that amount. The share price’s 52-week low was $11.66, which indicates that the current value has risen by an impressive 58.3% since then. We note from NovoCure Ltd’s average daily trading volume that its 10-day average is 2.55 million shares, with the 3-month average coming to 1.24 million.
NovoCure Ltd stock received a consensus recommendation rating of Buy, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended NVCR as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. NovoCure Ltd is expected to report earnings per share of -0.36 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
Instantly NVCR has showed a green trend with a performance of 5.11% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 32.60 on recent trading dayincreased the stock’s daily price by 14.23%. The company’s shares are currently up 87.27% year-to-date, but still up 39.52% over the last five days. On the other hand, NovoCure Ltd (NASDAQ:NVCR) is 54.48% up in the 30-day period. We can see from the shorts that 5.67 million shares have been sold at a short interest cover period of 4.31 day(s).
The consensus price target as assigned by Wall Street analysts is $30, which translates to bulls needing to increase their stock price by 6.8% from its current value. Analyst projections state that NVCR is forecast to be at a low of $30 and a high of $30.
NovoCure Ltd (NVCR) estimates and forecasts
NovoCure Ltd share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 30.05 percent over the past six months and at a 32.31% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be 17.20%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 153.05M in revenue for the current quarter. 2 analysts expect NovoCure Ltd to make 154.99M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 133.78M and 138.5M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 14.40%. Forecasts for the next quarter put sales growth at 11.91%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.97%.
NVCR Dividends
NovoCure Ltd’s next quarterly earnings report is expected to be released in January.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.26% of NovoCure Ltd shares, and 87.34% of them are in the hands of institutional investors. The stock currently has a share float of 96.25%. NovoCure Ltd stock is held by 325.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 15.0482% of the shares, which is about 16.14 million shares worth $276.51 million.
BLACKROCK INC., with 11.3106% or 12.13 million shares worth $207.83 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
